Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 2/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 9/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.33 |
| ▸ | KDM6A | O15550 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM4B | O94953 | 1/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.33 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8285627 | 0.88 | KDM4E (0.33) | TSPOKDM4EALDH1A1HSD17B10 | |
| SCHEMBL4284545 | 0.82 | KDM4E (0.37) | KDM4EALDH1A1LMNAHSD17B10 | |
| SCHEMBL1495229 | 0.82 | P2RX3 (0.37) | P2RX3KDM4EALDH1A1LMNAMAPK1 | |
| SCHEMBL8283679 | 0.80 | KDM4E (0.39) | TSPOKDM4EALDH1A1HSD17B10 | |
| SCHEMBL14003034 | 0.80 | KDM4E (0.39) | TSPOKDM4EALDH1A1HSD17B10 | |
| SCHEMBL14002666 | 0.79 | NOS2 (0.46) | KDM4EALDH1A1LMNAMAPK1NPSR1 | |
| SCHEMBL8284750 | 0.79 | KDM4E (0.38) | TSPOKDM4EALDH1A1LMNAMAPK1 | |
| SCHEMBL4288001 | 0.77 | LMNA (0.40) | KDM4EALDH1A1LMNAHSD17B10 | |
| SCHEMBL4281670 | 0.77 | KDM4E (0.36) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL4863283 | 0.76 | MAPT (0.45) | KDM4EALDH1A1LMNAMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1711485-B1 | AMINO-BENZIMIDAZOLES DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARM LTD (IE) | 2009-05-13 | — | — | EP | disclosed |
| US-20090036466-A1 | AMINO-BENZIMIDAZOLES DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | BONFANTI JEAN-FRANCOIS | 2009-02-05 | — | — | US | disclosed |
| US-20090036466-A1 | AMINO-BENZIMIDAZOLES DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | BONFANTI JEAN-FRANCOIS | 2009-02-05 | — | — | US | disclosed |
| US-20090036466-A1 | AMINO-BENZIMIDAZOLES DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | BONFANTI JEAN-FRANCOIS | 2009-02-05 | — | — | US | disclosed |
| WO-2005058870-A1 | AMINO-BENZIMIDAZOLES DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036466-A1 | AMINO-BENZIMIDAZOLES DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | NQO2, NOX3, NOX1 | TSPO 935/4885TOP2A 1771/4885P2RX3 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.